---
title: CRO Daily News — August 6, 2026
slug: daily-news-2026-08-06-cro
site: cro
post_kind: news
byline: BioBM
description: August 6 CRO daily: Cryoport Q2 2026: 8% Revenue Growth, 779 Clinical Trials Supported — Cryoport's 51-trial net increase and 25% BioStorage/BioServices…
canonical_url: https://www.cro.directory/posts/daily-news-2026-08-06-cro
published_at: 2026-08-06T23:59:40.454Z
last_updated: 2026-08-07T00:01:14.800Z
---

### Cryoport Q2 2026: 8% Revenue Growth, 779 Clinical Trials Supported
- Life Sciences Services revenue grew 15% year-over-year to $27.97 million; BioStorage/BioServices surged 25%.
- Cryoport supported 779 global clinical trials and 22 commercially approved cell and gene therapies as of June 30, 2026.
- Company achieved positive adjusted EBITDA in Q2 2026, marking a milestone on its pathway to sustainable profitability.

**Operational Impact**

Cryoport's 51-trial net increase and 25% BioStorage/BioServices growth reflect rising demand for integrated cold-chain logistics across CGT clinical pipelines, expanding its capacity to support Phase 3 advancement and commercial patient access.

*Source: [PR Newswire pharma category RSS](https://www.prnewswire.com/news-releases/cryoport-reports-second-quarter-2026-financial-results-302845362.html)*

## References

1. [PR Newswire pharma category RSS — Cryoport Q2 2026: 8% Revenue Growth, 779 Clinical Trials Supported](https://www.prnewswire.com/news-releases/cryoport-reports-second-quarter-2026-financial-results-302845362.html)

Source: https://www.cro.directory/posts/daily-news-2026-08-06-cro